http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102098709-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102098709-B1 |
| titleOfInvention | Repebody-Anticancer Protein Drug Conjugate having enhanced cell permeability, Preparation Methods and Use Thereof |
| abstract | The present invention provides a complex comprising a repebody, a cell permeation domain, and an anticancer protein drug, and a method for manufacturing the complex. More specifically, the lipobody or anti-cancer protein drug complex having improved cell permeability combined with a protein drug having a cell permeation domain and an anticancer activity to a lipid body or a protein derivative having a lipid body as a basic skeleton, a method of manufacturing and use thereof It is about. The lipid body-anticancer protein drug complex having improved cell permeability according to the present invention combines a protein drug capable of selectively killing only cancer cells with high substrate specificity and excellent tissue and tumor penetration capability provided by the lipid body and the cell permeation domain. As a result, it has superior efficacy compared to the case of using Lipibody alone, and has the advantage of being able to minimize side effects by having specific selectivity for target cells compared to the case of using protein drugs alone, It is expressed in a soluble form in E. coli, so it can be easily mass-produced at low cost, very thermodynamically stable, and has excellent tissue penetration properties. It is useful to kill. |
| priorityDate | 2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 756.